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Background: Photodynamic therapy (PDT) is becoming a promising therapeutic modality for hematological
malignancies. Hypericin is a natural photosensitizer possessing anti-depressant, anti-virus and anti-cancer activities.
The present study was designed to explore the effect and mechanism of hypericin-mediated PDT on the mouse
multiple myeloma (MM) cells in vitro.
Methods: The mouse myeloma SP2/0 cells were incubed with different concentrations of hypericin and then
illuminated with different light doses. The inhibitory effect of hypericin-mediated PDT on tumor cell proliferation
was assayed by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) method. The apoptosis related
morphological changes of SP2/0 cells were observed by microscopy. The biochemical hallmarks of apoptosis such
as DNA fragments, mitochondrial membrane potential changes were assessed. The expression of apoptosis related
proteins were investigated by western blotting.
Results: Hypericin-mediated PDT induced the proliferation inhibition and apoptosis of tumor cells in a dose dependent
manner. Tumor cells showed obvious morphological changes of apoptosis and necrosis and DNA fragmentation
after treated by hypericin mediated PDT (0.025 ~ 0.05 μM). The mitochondria membrane potential in SP2/0 cells was
decreased significantly after incubated with the 0.025 μM and 0.5 μM hypericin (P < 0.05). The expression level of
caspase-3 was decreased, while caspase activity was elevated with the increasing drug dosage. The apoptosis of SP2/0
cells was blocked by a pan-caspase inhibitor Z-VAD-FMK and caspase-3 inhibitor Ac-DEVD-CHO.
Conclusion: Hypericin-mediated PDT induced apoptosis mainly dependent on caspase related pathways.
Hypericin-mediated PDT may be a potential and alternative therapy for MM.
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Multiple myeloma (MM) as one of the lymphoid neo-
plasms, is characterized by the accumulation of ab-
normal plasma cells in bone marrow [1,2]. MM is the
second most common hematological malignancy, ac-
counting for 10% of all hematological malignancies. MM
can affect various organs function in patients and result
in a series of symptoms such as bone pain, renal failure,
infection and neurological disorders [3-6]. It is estimated
that total 14541 cases will suffer MM in the year of 2010* Correspondence: ruianxuraxer@163.com
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to 21754 by 2020 in India [7]. In addition, the overall
survival time for patients with MM ranges from 6
months to 10 years with mean of 3 to 4 years [8]. MM
remains an incurable hematological malignancy, despite
of conventional and advanced chemotherapy.
Presently, novel therapies are urgently needed. Photo-
dynamic therapy (PDT) is a potential novel anticancer
therapy that applied a photosensitizer and light to pro-
duce reactive oxygen in cells [9]. PDT can inactivate
tumor cells in autologous bone marrow grafts and shows
benefits in bone marrow transplantation substantially
[10]. PDT has been applied in eradicating the malignantticle distributed under the terms of the Creative Commons Attribution License
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transplantation for MM treatment [11]. Additionally, it is
reported that PDT exerts stronger cytotoxicity in chronic
myeloid leukemia (CML) cells than normal granulocyte/
macrophage progenitors and PDT can eliminate CML
cells from malignant-normal bone marrow mononuclear
cells mixture [12]. PDT is becoming a promising thera-
peutic modality for hematological malignancies, such as
leukemia [13], lymphoma [14] and MM [11].
Hypericin, a natural polycyclic quinone, is mainly ex-
tracted from the plants of hypericum genus [15]. Hyperi-
cin has been regarded as a promising photosensitizing
agent for its characteristic of light-dependent antineoplas-
tic and antiviral activity [16]. Hypericin-mediated PDT has
obtained increasing interests as a potential treatment for
various cancers [17-19]. Currently, multiple pathways have
been found to involved in the tumor cell death program
induced by hypericin-mediated PDT, such as mitochon-
drial pathway [20,21], lysosomal damage [22], alternation
of intracellular pH level [23,24], Bcl-2 phosphorylation by
CDK-1 [25] as well as the increase of intracellular Ca2+
stimulated apoptosis [26-28]. However, the mechanism
underlying hypericin-mediated PDT for MM suppression
has been not clarified clearly.
In this study, we explore the mechanism of MM treat-
ment and the type of cell death induced by PDT with
hypericin by SP2/0 cells. The cellular morphology and
the cell proliferation of SP2/0 cells were investigated at
different concentrations of hypericin. The changes in the
mitochondrial membrane potential and the activation of
Caspase related pathways were further assessed. The aim
of the present study was to investigate the effect and
mechanism of hypericin-mediated PDT on the mouse
MM cells in vitro.
Materials and methods
Hypericin preparation and cell culture
Hypericin powder (Beijing Standard Herbs Medical
Science & Technology Development Co. LTD., Beijing,
China) with purity > 98% was determined by high-
performance liquid chromatography (HPLC). A stock
solution of hypericin (10 mM) was prepared with dimethyl
sulfoxide (DMSO; Sigma) and stored at −20°C in the dark.
Immediately before each experiment, the working solution
of hypericin was diluted in RPMI1640 medium without
serum to obtain a final concentration.
The mouse myeloma cell line SP2/0 (ATCC) was from
American Type Culture Collection. The cells were cul-
tured in RPMI1640 medium supplemented with 10% calf
serum, 2.2 g/l NaHCO3, 100 U/ml penicillin, and 100 g/ml
streptomycin. Cells were maintained in a humidified at-
mosphere with 5% CO2 at 37°C until the logarithmic
growth phase based on the cell growth curve. The adhe-
rent cells were displaced by rinsing with 0.25% trypsin.Then, the adherent and suspension cells were harvested
for the following experiments.
PDT treatment
SP2/0 cells (5 × 104 cells/ml) were seeded on 96-well
plates (100 μl/well) and incubated with hypericin at dif-
ferent concentration (0.001, 0.01, 0.1, 1 and 10 μM) for
16 hours in the dark. Cells were given external 7 cm illu-
mination treatment on a plastic diffuser sheet above a
set of 6 yellow L18W/30 lamps (CH Lighting, Zhejiang,
China) with the maximum spectrum range of 570–620
nm. Irradiation intensity was detected to be under 13000
lux by TES-1332A (TES, Taiwan, China). The total light
doses were determined to be 2.82, 5.64, 8.46, 11.28 and
14.10 J/cm2 by a photometer. During the illumination,
the temperature of the samples ranged from 32 to 37°C.
After PDT treatment, cells were maintained for 24 hours
at 37°C in a humidified atmosphere of 95%, 5% CO2
until further analysis.
The 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide (MTT) assay
In order to determine the optimal hypericin concentration
or irradiation dose for PDT treatment, we performed
MTT assay to analyze the proliferation of SP2/0 cells [29].
Briefly, SP2/0 cells at a final density of 5 × 104 cells/ml
(100 μl/well), were incubated with hypericin at a concen-
tration gradient from 0.001 to 10 μM for 16 hours in the
dark. The cell plates were illuminated with different light
dose of 0, 2.82, 5.64, 8.46, 11.28 and 14.10 J/cm2, and then
incubated for 24 hours in the dark. To obtain the IC50,
SP2/0 cells were treated with indicated concentrations of
hypericin (0, 0.0125, 0.025, 0.05 and 0.1 μM) for 16 hours
in the dark. Subsequently, the cells were illuminated at a
light dose of 11.28 J/cm2 for 24 hours in the dark.
SP2/0 cells without any treatment were set as controls.
The MTT assay was performed for SP2/0 cells at each
condition according to the manufacturer’s instructions. In
brief, 10 μl of MTT (5 mg/ml; Sigma) was added in each
well for 4 hours at 37°C. After removal of the medium,
the MTT crystals were dissolved with 100 μl DMSO for
15 min. The absorbance at 550 nm was measured by a
Multiskan Spectrum 1500 (Thermo Electron Corpor-
ation, USA). The inhibition rate of cell proliferation
was calculated as follows: (A550control − A550treated)/
A550control × 100% and the IC50 value was obtained by
Logit method [30].
Light and fluorescence microscopy
SP2/0 cells (1 × 105cells/ml) were seeded into the 6-well
plates (2 mL/well) and incubated with hypericin at the
final concentrations of 0.025, 0.05 or 0.1 μM for 16
hours in the dark. Subsequently, the plates were illu-
minated at a light dose of 11.28 J/cm2 for 24 h. The
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lowing morphological analysis according to the method
described above.
A part of cells were harvested and observed by a phase-
contrast microscopy. Some cells were collected for
Hoechst 33342/propidium iodide (PI) co-staining [31].
SP2/0 cells were stained with Hoechst 33342 (5 μg/ml)
and PI (5 μg/ml) at room temperature for 10 min, then
examined under a fluorescence microscopy (E600, Nikon,
Japan) with excitation at 360 nm [32]. Intact blue nuclei of
viable cells, condensed/fragmented bright blue nuclei of
apoptotic (early or late) cells and pink nuclei of necrotic
cells can be observed. The number of apoptotic or nec-
rotic cells was counted in a total of 200 cells from 5 ran-
dom fields.
Transmission electron microscopy (TEM)
SP2/0 cells (1 × 105cells/ml, 2 mL/well) treated with hyperi-
cin (0.025, 0.05 or 0.1 μM) and illumination (11.28 J/cm2)
were collected for TEM examination. Samples were pre-
pared as described previously [33]. The cells were fixed
with 2.5% glutaraldehyde, followed by 1% OsO4 and
then dehydrated with acetone. They were embedded in
Epon812-resin mixture. Serial sections (about 50 nm)
were obtained by ultra-microtome. Sections were stained
with sodium acetate and lead citrate and then viewed by a
Hitachi H-7000/STEM electron microscope (Hitachi Inc.,
Tokyo, Japan) at 75 kV.
DNA fragments
SP2/0 cells with hypericin (0.025, 0.05 and 0.1 μM) and
illumination (11.28 J/cm2) were used for this experiment.
The suspension cells and adhesive cells on the 6-well
plates were all collected for DNA extraction following
the manufacturer’s instructions of DNA Ladder Extraction
Kit with Spin Column (Beyotime Institute of Biotechnology,
China). The DNA extractions (40 μg) were separated on
1.0% agarose gel containing ethidium bromide (EB) and
were visualized under UV light. Standard molecular
weight markers (Fermentas, MBI) were run on the left-
hand lane of the gel.
The 5, 5′, 6, 6′-tetrachloro-1, 1′, 3,
3′-tetraethylbenzimidazolyl-carbocyanine iodide (JC-1)
staining
In order to explore the changes in the membrane poten-
tial, we carried out JC-1 staining for SP2/0 cells intervened
by hypericin (0, 0.025 and 0.05 μM) and illumination
(11.28 J/cm2). The collapse of the mitochondrial mem-
brane was measured using a mitochondrial membrane
potential assay kit with JC-1 (Beyotime Institute of
Biotechnology, China) [34]. JC-1 formed aggregates in
the mitochondria at relatively high membrane potential
exhibiting red-orange fluorescent at 590 nm. The JC-1monomers distributed in the cytoplasm of cells with low
potential and emitted a green fluorescent at 529 nm.
After JC-1 staining, cells were analyzed by flow cytome-
try with green emission in channel 1 (FL1) and red
emission in channel 2 (FL2). The relative ratio of JC-1
aggregate (FL2, red fluorescence intensity) to monomer
(FL1, green fluorescence intensity) was calculated. A de-
crease in this ratio was defined as the depolarization of
the mitochondrial membrane potential.
Propidium iodide (PI) staining
To evaluate the effects of caspase inhibitors (pan-caspase
inhibitor Z-VAD-FMK or caspase-3 inhibitor Ac-DEVD-
CHO) on apoptosis mediated by hypericin with PDT, the
PI staining was carried out. The caspase inhibitors were
dissolved in DMSO at a storage 20 mM concentration.
SP2/0 cells were pre-incubated with the pan-caspase in-
hibitor (100 μM) or caspase-3 inhibitor (100 μM) for 1 h,
and then exposed to 0.05 μM hypericin for 16 h in the
dark. Preliminary experiment indicated that 0.125%
DMSO had little effect on the cell death and proliferation.
For PI staining, the caspase inhibitors were dissolved in
0.05% DMSO that was safe for SP2/0 cells. After illumi-
nated at 11.28 J/cm2 for 24 h, SP2/0 cells were harvested,
fixed in 70% ethanol and stored at 4°C overnight. Then,
cells were stained with PBS containing 40 μg/mL RNase
and 10 μg/mL PI at room temperature for 30 min in the
dark. Cells were analyzed using an FACS-Calibur flow
cytometer (Becton Dickinson, San Jose, CA, USA). The
cells during apoptosis were obtained from the distinct
sub-G1 region of the DNA distribution histograms. At
least 20,000 events were counted for each sample.
Caspase-3 activity assay
SP2/0 cells at a final density of 1 × 105 cells/ml were
grown in 6-well plates (2 mL/well) and incubated with
the hypericin (0.025 and 0.05 μM) for 16 hours. The un-
treated cells were defined as control. After 24 h illumin-
ation at 11.28 J/cm2, caspase-3 activity was determined
using a caspase-3 activity kit (Beyotime, Nanjing, China)
which was based on the ability of caspase-3 to change
acetyl-Asp-Glu-Val-Asp p-nitroanilide into the yellow
formazan product, p-nitroaniline. The absorbance at 405
nm was measured for cells treated with hypericin with
PDT and controls. The formula was listed as follows:
Activity of caspase 3 ¼ OD405nm of treated cells
OD405nm of controls
Western blotting
Western blot analysis was performed as previously de-
scribed [35-37]. Protein samples (40 μg) were separated
by 8-12% (8% for PARP-1; 10% for AIF, β-actin; 12% for
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dium dodecyl sulfate-polyacrylamide gels electrophoresis
and transferred to polyvinylidene fluoride membrane
(Immobilon PVDF, Millipore). The membranes were
blocked in 10% non-fat dried milk in TBS-T (10 mM
Tris–HCl (pH 8.0), 150 mM NaCl, and 0.1% Tween) for
2 hours at room temperature. Then the membranes were
incubated with the primary antibodies of anti-Bcl-2 rabbit
monoclonal antibody (1:1000), anti-Bax rabbit mono-
clonal antibody (1:1000), anti-caspase-3 rabbit polyclonal
antibody (1:1000), anti-PARP rabbit polyclonal antibody
(1:1000), anti-β-actin mouse polyclonal antibody (1:1000),
anti-cytochrome c rabbit monoclonal antibody (1:1000),
anti-AIF rabbit monoclonal antibody (1:1000), and anti-
H2AX rabbit monoclonal antibody (1:500), respectively,
overnight at 4°C. All the antibodies were purchased from
Cell Signaling Technology (Beverly, MA, USA). Subse-
quently, membranes were washed three times with Tris-
bufffered saline, 0.1% Tween-20 and then incubated with
the peroxidase-conjugated secondary antibodies for 1 h.
The membranes were washed three times again and deve-
loped using enhanced chemiluminescence (ECL, Amersham
Biosciences). Bands were visualized using the ChemiDoc™
XRS+ System with Image Lab™ Software (Bio-rad, USA).
Protein expressions were quantified by densitometry
analyzed using Quantity One 4.5.2 software (Bio-Rad,
Hercules, USA).
Statistical analysis
All the data were displayed as mean ± standard devia-
tion (SD). All the statistical analysis was performed by
SPSS17.0 statistical software. Differences among groups
were analyzed with S-N-K followed by One-Way ANOVA.
P value < 0.01 was considered to be statistically significant.
Results
Hypericin mediated PDT inhibited the proliferation of
SP2/0 cells
The inhibitory effect of hypericin on the proliferation of
SP2/0 cells was determined following photoactivation.
As shown in Figure 1A, treatment of hypericin or PDT
alone showed little effect on preventing the proliferation
of SP2/0 cells. After the cells were incubated with diffe-
rent concentrations of hypericin (0.001, 0.01, 0.1, 1 and
10 μM) for 16 hours and then exposed to various flu-
encies of irradiation (0–14.10 J/cm2), the proliferation of
SP2/0 cells was inhibited significantly with the increa-
sing drug concentration and light dose. When cells were
irradiated with 8.46 J/cm2 light dose, the inhibition rates
of cell proliferation were 2.20 ± 0.76%, 26.19 ± 0.95%,
75.75 ± 0.93%, 90.07 ± 1.35% and 95.88 ± 1.26% with the
hypericin concentrations ranging from 0.001 to 10 μM,
respectively. Similarly, for the cells with 0.1 μM hyperi-
cin treatment, the inhibitory rates were 2.51 ± 0.79%,50.1 ± 0.88%, 75.75 ± 0.93%, 95.53 ± 0.89% and 96.25 ±
1.05% at 2.82 to 14.10 J/cm2 light doses, respectively. In
addition, with the high hypericin concentration of 1 μM,
cells showed similar proliferation inhibitory rate of 82.68%
and 87.89% at light dose of 11.28 and 14.12 J/cm2, respec-
tively (P > 0.05). Therefore, the light dose of 11.28 J/cm2
was selected for further experiments.
There was a positive linear correlation between the in-
hibition rate and hypericin concentration (R2 = 0.955)
and the value of IC50 was 0.035 ± 0.003 μM at condition
of hypericin (0, 0.0125, 0.05 or 0.1 μM) with light dose
of 11.28 J/cm2 (Figure 1B). These results suggested that
hypericin-mediated PDT inhibited the proliferation of
SP2/0 cells effectively in a concentration and light-dose
dependent manner.
Hypericin-mediated PDT induced obvious morphological
changes of apoptosis in SP2/0 cells
After hypericin mediated PDT treatment for 24 hours,
phase-contrast microscopy observation showed that
SP2/0 cells had obvious morphological changes such as
cell shrinkage and membrane bleb formation in a drug
concentration-dependent manner, in comparison of un-
treated cells (Figure 2A). As shown in Figure 2B and D,
most of the nuclei were round and blue in controls with
the percentage of 94.97 ± 0.26%. Bright apoptotic nuclei
characterized by chromatin condensation or fragments
were found in the groups treated by PDT with hypericin
at 0.025 and 0.05 μM and the percentage of apoptotic cells
was 39.18 ± 1.34% and 63.52 ± 2.81%, respectively. While
in the 0.1 μM hypericin with PDT treatment group, most
nuclei (71.84 ± 3.09%) were diffused and stained with pink,
and there were a few bright condensed nuclei.
Furthermore, TEM analysis revealed that hypericin-
mediated PDT induced obvious morphological changes of
SP2/0 cells. The control cells showed abundant cytoplasm
and apparent nuclei with uniformly dispersed chromatin.
After exposed to 0.025 μM hypericin with PDT, cells ex-
hibited the typical characteristics of early stage apoptosis
such as nuclear membrane contraction and chromatin
marginalization. When exposed to 0.05 μM hypericin with
PDT, cells were characterized by nuclear fragmentation,
intense vacuolization and a large number of apoptotic
body formations. At the condition of 0.1 μM hypericin
with PDT, there appeared the necrotic cell death, which
displayed ruptured plasma membrane, swollen mitochon-
drial, irregular chromatin destruction (Figure 2C).
Hypericin-mediated PDT induced DNA fragmentation in
SP2/0 cells
In order to assess the hallmark of apoptosis in seSP2/0
cells responding to the treatment of hypericin-mediated
PDT, DNA from SP2/0 cells at different hypericin con-
centrations of 0.025, 0.05 and 0.1 μM were extracted
Figure 1 Proliferation of SP2/0 cells determined by MTT assay. (A) SP2/0 cells were treated with different concentrations of hypericin (0-10 μΜ)
and irradiation doses (0–14.12 J/cm2) for 24 hours. (B) SP2/0 cells were treated with different concentrations of hypericin (0–0.1 μΜ) and
irradiation dose of 11.28 J/cm2) for 24 hours. Results were shown as mean ± SD, n = 5, *p < 0.01.
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shown in Figure 3, PDT mediated cells treated by hy-
pericin at concentration of 0.025, 0.05 μM exhibited a
characteristic DNA laddering by agarose gel electropho-
resis. However, there were limited fragments for DNA
from 0.1 μM hypericin treated cells and no DNA frag-
ments were observed in untreated cells and cells treated
with PDT alone.Hypericin-mediated PDT induced loss of mitochondria
membrane potential in SP2/0 cells
The changes in the mitochondrial membrane potential
of SP2/0 cells were detected by JC-staining with flow
cytometry. After hypericin-mediated PDT treatment, the
red-orange mitochondrial fluorescence decreased, while
more of the green fluorescence (JC-1 monomer) was ob-
served in cytoplasm (Figure 4A,B). Compared with cellswith only post-radiation therapy (3.61), the ratio of
JC-red/JC-green was significantly decreased in cells in-
tervened by PDT with hypericin at 0.025 μM (1.74) and
0.05 μM (0.47), (P < 0.05) which suggested that the loss
of mitochondrial membrane potential (Figure 4C).Hypericin-mediated PDT activated both caspase-dependent
and AIF mediated caspase-dependent signaling pathways
The protein levels in SP2/0 cells treated by hypericin-
mediated PDT (0.025 and 0.05 μM) for 24 h were ana-
lyzed. Western blot analysis showed that the expression
of Bcl-2 was down-regulated by 35%, while the expres-
sion of Bax was up-regulated by 13.4%. Thus, the Bax/
Bcl-2 ratio increased from 1 to 3.6 folds, compared with
cells in control (0 μM hyericin treatment). Additionally,
hypericin-mediated PDT induced the increased expres-
sion of cytochrome c and AIF (Figure 5). Furthermore,
Figure 2 (See legend on next page.)
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Figure 2 Morphological changes assayed in SP2/0 cells exposed to the indicated concentrations of hypericin at 24 h after applying 11.28 J/cm2
irradiation dose. (A) Light microscopy analysis of morphological alternations in SP2/0 cells. (a) Untreated control cells. (b), (c) and (d) Cells treated
with hypericin at 0.025, 0.05 or 0.1 μΜ. Bar = 10 μm (B) Apoptotic or necrotic nuclei of SP2/0 cells evaluated using fluorescence microscopy with
Hoechst 33342 (blue)/PI (red) double staining. (a) Untreated control cells. (b), (c) and (d) Cells treated with hypericin at 0.025, 0.05 or 0.1 μΜ.
Arrow: apoptotic nuclei; Arrow head: necrotic nuclei. Bar = 10 μm. (C) TEM analysis of ultrastructural alternations of SP2/0 cells. (a) Untreated
control cells. (b), (c) and (d) Cells treated with hypericin at 0.025, 0.05 or 0.1 μΜ. Arrow: apoptotic bodies; Arrow head: swollen mitochondria.
(D) The percentage of apoptotic or necrotic nuclei was analyzed in a total of 200 cells from five random areas.
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caspase activity was elevated with the increasing drug
dosage (Figures 5 and 6). The caspase-3-mediated cleav-
age of the 116-kDa PARP protein into 89-kDa was also
enhanced in a dose-dependent manner and 0.05 μM
hypericin-mediated PDT caused almost complete cleav-
age (Figure 5).Figure 3 Analysis of DNA fragments from SP2/0 cells treated with the indi
irradiation dose by agarose gel electrophoresis. Mr: maker; Con: control.Hypericin-mediated PDT induced apoptosis dependent
on caspase
To investigate whether apoptosis induced by hypericin-
mediated PDT dependent on the activation of capases,
SP2/0 cells were pretreated with the 100 μM pan-caspase
inhibitor (Z-VAD-FMK) or 100 μM caspase-3 inhibitor
(Ac-DEVD-CHO) for 1 h. Flow cytometry analysis showedcated concentrations of hypericin at 24 hour after applying 11.28 J/cm2
Figure 4 The mitochondrial membrane potential of SP2/0 cells detected by JC staining with flow cytometry. A: Fluorescence intensity detected
by channel 1 (FL1); B: Fluorescence intensity detected in channel 2 (FL2); C: Mitochondrial membrane potential was expressed as the ratio of
FL-2/FL-1. (a) Untreated control cells; (b) Cells treated with hypericin at 0.025 μM; (c) Cells treated with hypericin at 0.05 μΜ. **P < 0.05 compared
with untreated controls.
Figure 5 Hypericin-mediated PDT regulates Bcl-2 family proteins
expression, induces loss of the mitochondrial membrane potential
and results in cleavage of caspase-3 and PARP. (A) SP2/0 cells were
treated with hyerpicin-mediated PDT for 24 h. Whole cell lysate was
prepared and assayed for Bcl-2, Bax, Caspase-3 and PARP proteins,
cytosol fractions were used to assay cytochrome c and nucleus
fractions were used to assay AIF. Relative protein expression is shown
at the bottom of each panel, with control levels arbitrarily set to 1.
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controls, while the apoptosis rate was up to 56.47% in the
hypericin-mediated PDT group (0.05 μM) (Figure 7).
Moreover, the apoptosis rate of cells pretreated with zVAD-
fmk (5.32%) or Ac-DEVD-CHO (7.43%) decreased ob-
viously after hypericin- mediated PDT treatment (Figure 7).
Discussion
MM is the most common bone marrow malignancy. It is
reported that there are 114,000 cases diagnosed with
MM and 80,000 deaths resulting from MM in 2010
worldwide [38]. MM remains an incurable bone malig-
nancy with severe complications and poor prognosis for
MM patients. The increasing studies for MM treatment
contribute to the evolution of therapies, the increase of
survival time and the improvement of life quality for pa-
tients [39]. Hypericin-mediated PDT is reported to be an
attractive candidate treatment modality for human cancer
cells [40]. The evidence of the inhibitive effect of hypericin-
mediated PDT on MM is insufficient. In this study, we
further explored the mechanism of the apoptosis of mouse
myeloma SP2/0 cells induced by hypericin-mediated PDT
at different concentrations of hypericin.
Our results showed that the combination of hypericin
with PDT showed great inhibitive effects on the prolife-
ration of SP2/0 cells and led to extensive apoptosis.
After tumor cells were incubated with different concen-
trations of hypericin (0.01-10 μM) and then exposed to
illumination with different light doses (0–14.10 J/cm2),
data from MTT assay revealed that hypericin or illumi-
nation treatment alone had no obvious effect on inhibi-
ting the proliferation of SP2/0 cells. Hypericin combined
with illumination caused significant drug concentration-
Figure 6 Caspase-3 activity assay. SP2/0 cells were treated with
hypericin (0.025 or 0.05 μM) for 16 hours. At 24 hour after 11.28 J/cm2
irradiation, caspase-3 activity was measured by colorimetric method.
Y axis represents the caspase-3 activity (OD405nm of treated cells/
OD405nm of controls).
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of SP2/0 cells proliferation. The metabolic activity of
SP2/0 cells was reduced significantly with the increasing
hypericin concentration and light dose. Additionally, we
found that under the same concentration of hypericin,
high light dose (11.28 and 14.10 J/cm2) caused compar-
able effect on the cell proliferation inhibition, and the
higher concentrations of hypericin (1 and 10 μM) caused
equal inhibitory effect on the tumor cell proliferation,Figure 7 The effects of different caspase inhibitors on apoptosis induced b
pan inhibitor Z-VAD-FMK (100.0 μM) or caspase-3 inhibitor Ac-DEVD-CHO (10
At 24 hour after 11.28 J/cm2 irradiation, apoptosis was assayed by flow cytom
CHO; D: hypericin + Z-VAD-FMK.under the same illumination, which indicated that there
might be a saturation of photochemical dose in PDT
treatment on the MM. In order to avoid the damage
caused by excess photosensitizing drug, the optimal
treatment condition leading to the appropriate energy
state results for MM patients should be further studied.
Apoptosis has been determined to be the most promi-
nent event in the tumor tissue destruction induced by
hypericin-mediated PDT [41,42]. In order to assess the in-
volvement of apoptosis in tumor response to hypericin-
mediated PDT, the hallmarks of apoptosis including DNA
fragmentation and morphological changes were investi-
gated in this paper. Results showed that low doses of PDT
with hypericin (0.025 and 0.05 μM) induced apparent
morphological and biochemical characteristics of apop-
tosis in SP2/0 cells such as cell shrinkage, chromatin
condensation, formation of apoptotic bodies as well as
DNA laddering, while high dose of PDT with hypericin
(0.1 μM) led to cell necrosis (Figures 2 and 3). As outlined
in previous studies, apoptosis induced by PDT can be ob-
served at lower hypericin concentrations and fewer light
intensities, whereas necrosis occurs at high hypericin
concentrations and light intensities [43,44], which is con-
sistent with our findings. The transitions from apoptosis
to necrosis in a drug and light dose-dependent manner
induced by hypericin with PDT have also been observed
in HeLa cells and human epidermoid carcinoma cells
in vitro [20,21]. All these showed that hypericin-mediated
PDT is a potent inducer of apoptosis or necrosis in MM
SP2/0 cells depended on the dosage of PDT, despite of the
factors such as the location of the photosensitizer, the
nature of photosensitizer as well as the genetic and meta-
bolic potential of the cell type.
It is demonstrated that the apoptosis induced by
hypericin-mediated PDT mainly resulted from the acti-
vation of apoptosis related pathways in response to the
oxidative stresss and other signals [45]. It is reported that
the apoptosis pathways induced by hypericin-mediatedy hypericin mediated PDT. SP2/0 Cells were pretreated with caspase
0.0 μM) for 1 h, and then exposed with 0.05 μM hypericin for 16 hours.
etry after staining with PI. A: control; B: hypericin; C: hypericin + Ac-DEVD-
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mitochondria, lysosomes and ER, caspases, and Bcl-2
family proteins [46]. Bcl‑2 family proteins play key roles in
the mitochondria-mediated cell death [47]. The expression
of Bcl‑2 family proteins can induce the mitochondrial
membrane permeabilization, which causes the release of
caspases or apoptosis inducing factor (AIF) [48]. The up-
regulation of Bax/Bcl-2 ratio is found to be associated
with the decrease of mitochondrial membrane potential
that inhibits the growth of cancer cell growth [49].
In the present study, results of western blotting sug-
gested that the expression of anti-apoptotic Bcl-2 pro-
tein was decreased and pro-apoptotic Bax protein was
increased induced by hypericin-mediated PDT and thus
shifted the Bax/Bcl‑2 ratio that leaded to loss of the
mitochondrial membrane potential in favor of cytochrome
c and AIF release. In the apoptosis process, the release of
cytochrome c induced the activation of caspase-9 and then
activates caspase-3 [50]. Caspase-3-mediated cleavage of
the 116-kDa PARP protein into 89-kDa fragments is a
hallmark of apoptosis [51]. The present study also showed
that caspase-3 activity was increased that contributed to
PARP cleavage and DNA degradation.
In fact, cytochrome c-mediated capsase dependent
apoptotic pathway and AIF mediated caspase independent
apoptotic pathway are complicated but not completely in-
dependent. AIF in the cytosol could promote cytochrome
c to be released from mitochondria and the activated cas-
pases also facilitate translocation of AIF from mitochon-
dria to the nucleus [52]. Besides, the present study further
showed that the apoptosis induced by hypericin-mediated
PDT was inhibited significantly by the pan-caspase inhibi-
tor zVAD-fmk or special caspase-3 inhibitor Ac-DEVD-
CHO. All these indicated that AIF release might be
facilitated by casapse and hyerpicin with PDT induced
apoptosis mainly depended on caspase-mediated cell
death pathways.Conclusions
Hypericin-mediated PDT could significantly inhibit the
proliferation and induce apoptosis in myeloma SP2/0
cells. The apoptosis induced by hypericin-mediated PDT
mainly depended on the caspase-mediated cell death
pathway. Hypericin-mediated PDT may be a promising
and alternative strategy for the treatment of MM.
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